Jung M, et al. - This research was designed to assess the efficacy and safety of ramucirumab outside of a clinical trial using an expanded access program (EAP). Ramucirumab showed similar efficacy as seen in the results of previous trials for gastric cancer in the Korean EAP cohort. However, in the ramucirumab plus paclitaxel group, the level of gastrointestinal (GI) perforation was slightly increased.